Update on combined immunotherapy for the treatment of advanced renal cell carcinoma

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma

There has been substantial evolution in the treatment of metastatic renal cell carcinoma with notable changes in the first-line setting. Currently, doublet combination therapy with either two immune checkpoint inhibitors or a combination of an immune checkpoint and tyrosine kinase inhibitor is consi...

Full description

Bibliographic Details
Main Authors: Georges Gebrael, Kamal Kant Sahu, Neeraj Agarwal, Benjamin L. Maughan
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immune checkpoint inhibitors
renal cell carcinoma
immunotherapy
pd-1
pd-l1
Online Access:http://dx.doi.org/10.1080/21645515.2023.2193528

Similar Items

Similar Items